There's a Critical Thing We Can All Do to Hold Alzheimer's Symptoms at Bay
In their study of 62 older, cognitively healthy adults, researchers from the University of California (UC) Berkeley, Stanford University, and UC Irvine in the US found individuals with brain changes associated with Alzheimer's performed better on memory function tests as they got more deep sleep.
This was irrespective of education and physical activity, two factors along with social connection known to contribute to cognitive resilience in older age.
Those with similar Alzheimer's-linked changes who failed to get as much deep sleep didn't fare quite as well on the same tests. By comparison, sleep made little difference to those individuals with few deposits.
Taken together, the results, which were published in May 2023, imply having a generous amount of solid shut-eye could help support the decline in memory that sets in as dementia begins to take hold.
Watch the following video for a summary of the study:
"Think of deep sleep almost like a life raft that keeps memory afloat, rather than memory getting dragged down by the weight of Alzheimer's disease pathology," said University of California (UC) Berkeley neuroscientist Matthew Walker.
"This is especially exciting because we can do something about it. There are ways we can improve sleep, even in older adults."
The study echoes previous research which has found a build-up of amyloid-beta proteins in the brains of people with disrupted sleep.
But poor sleep is both a risk factor for and a symptom of Alzheimer's disease, making it tricky to tease apart cause and effect. Likewise, clumpy amyloid-beta proteins might only be a sign of Alzheimer's disease, not its root cause.
Related:
Even so, levels of amyloid-beta proteins are commonly used as a marker of Alzheimer's disease, as research suggests they – and another protein called tau – can start clogging up brain cells decades before symptoms of the disease arise.
Past research from Walker's group found significant levels of amyloid-beta aggregating in the brains of older adults can disrupt deep sleep – also known as non-rapid eye movement slow wave sleep – and impair memory function.
But some folk appear to stave off the decline that comes with Alzheimer's disease, even when levels of amyloid-beta proteins are relatively high. To find out why, Walker and colleagues monitored participants' brain waves as they slept, and then asked them to complete a memory test the next day.
Among those whose brain scans revealed similarly high levels of beta-amyloid deposits, getting a good night's sleep seemed to make a critical difference in cognitive function.
This effect was only seen when the researchers looked specifically at non-rapid eye movement slow wave sleep, and not at other sleep wave frequencies or sleep stages.
Longer-term studies in older adults are needed to test whether increasing deep sleep over a number of years can actually help preserve a person's cognitive function in that time, even as levels of amyloid-beta increase.
This research adds to scores of studies suggesting that sleep could be a modifiable risk factor for Alzheimer's disease, one that could potentially forestall molecular changes by giving the brain time to clean up waste products that accumulate during the day. It also points to sleep quality being important.
"With a certain level of brain pathology, you're not destined for cognitive symptoms or memory issues," UC Berkeley neuroscientist and lead author Zsófia Zavecz said of the study findings in 2023.
Although people may display molecular changes indicating a progression toward Alzheimer's disease, Zavecz says their findings suggest lifestyle factors can help buffer against those effects. "One of those factors is sleep and, specifically, deep sleep," she said.
The study, though small, also hints at why getting good sleep naturally might be a better option than taking sleeping pills to get some shut-eye.
Other research shows users of sleeping pills appear to have lower levels of amyloid proteins in their cerebrospinal fluid, which washes the brain clean at night. But these medications come with side effects; they may also lull people into shallow bouts of sleep rather than deep sleep phases.
Instead, to set yourself up for a good night's sleep, Zavecz suggests cutting out coffee late in the day, doing some exercise, avoiding screen time, and taking a hot shower before bed.
While you snooze, rest assured scientists are working hard to figure out the knotty problems of Alzheimer's disease, which affects millions of people worldwide.
The study has been published in BMC Medicine.
A version of this article was first published in May 2023.
Ozempic Alternative Ditches The Needle And One Major Side Effect
A Simple Change To Your Evening Routine Could Help You Exercise More
'Sky-High' Levels of Alzheimer's Protein Found in Newborns
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Washington Post
an hour ago
- Washington Post
Asking Eric: After ugly comments, brother invites himself to party
Dear Eric: Nearly eight months ago, my 81-year-old brother lashed out saying hateful and hurtful things about our youngest sister. At the time, I suspected he was drunk and probably frustrated from the repeated episodes of our sister's illnesses and problems, some of which have been caused by her own serious eating disorder, depression and occasional binge drinking.
Yahoo
2 hours ago
- Yahoo
Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks
With persistent macro uncertainty and shifting market trends, healthcare remains one of the most defensive and fundamentally sound sectors for investors. The US healthcare industry continues to deliver both stability and long-term growth potential. In the latter half of 2025, these three healthcare stocks emerge as top picks for their compelling mix of innovation and favourable industry trends. Johnson & Johnson (J&J) is a global healthcare company with its core businesses in innovative medicine and MedTech. In the first quarter of 2025 (1Q 2025), J&J reported 2.4% year-on-year (YoY) increase in revenue, bringing in US$21.9 billion. This growth can be attributed to a strong revenue growth of 4.2% YoY in innovative medicine. A key driver for the rise is the 20.4% YoY in revenue growth in the oncology segment. This increase is due to medicine such as DARZALEX and ERLEADA experiencing share gains amid market growth.J&J's MedTech division recorded a strong 4.1% YoY revenue growth. The cardiovascular segment led this jump in revenue with a 17% YoY revenue growth. This growth is due to strong global procedure volumes and successful new product launches. The firm's internal forecast for sales of its key products by 2027/2028 is also higher than current market estimates. For instance, its pipeline product, the intravesical drug releasing system, is forecasted to have three times the product sales compared to current market estimates by 2027/ presents an opportunity for investors to capitalise on the potential upside which is not yet priced into the stock. This upside will be driven by J&J's internal forecasts, which signal confidence in its operations. Thermo Fisher is a top name in biopharmaceutical research, particularly in drug discovery and 1Q 2025, Thermo Fisher reported revenue of US$10.36 billion, along with organic revenue growth of 1% YoY. The firm's net profits climbed 13.5% YoY to US$1.5 billion in 1Q 2025. This strong growth was supported by the increased operational efficiencies with the partnership with the Chan Zuckerberg Institute for Advanced Biological partnership pioneers new technologies for improved human cell visualisation, providing scientists with better data insights and accelerating research cycles. In February 2025, Thermo Fisher also announced a US$4.1 billion acquisition of Solventum's Purification & Filtration Purification & Filtration business offerings enhance Thermo Fisher's current bioproduction services. This acquisition boosts Thermo Fisher's biologics production capabilities, thereby improving productivity. This deal also opens opportunities to cross-sell filtration and purification solutions alongside existing bioprocessing offerings. These developments demonstrate an effective strategic fit and may result in service margin expansion. UnitedHealth Group runs two primary businesses – UnitedHealthcare for healthcare insurance plans and Optum for technology-based healthcare services. UnitedHealth Group reported a 9.8% YoY increase in revenue in 1Q 2025, reaching US$109.6 billion. The company's net margin also improved to 5.7% in the same quarter. The previous year's quarter saw a net loss margin of 1.4%. The better performance was attributed to a strong performance for both UnitedHealthcare and Optum. In 1Q 2025, UnitedHealthcare's revenue grew by 12.2% YoY to US$84.6 billion. This growth was driven by a rise of 700,000 in the number of self-funded commercial plans sold. Another factor was the increased participation in senior and community-based offerings with 545,000 new members. In the same period, Optum saw an increase in revenue of 4.6% YoY to US$63.9 billion. This rise is led by a growth of Optum Rx which had an increase of 13 million scripts from new clients and deepening of existing relationships compared to 2024. Optum Insight also introduced artificial intelligence claim processing tools which increase productivity by over 20%. Moving forward, Optum Health announced its continued expansion of value-based care to serve 650,000 new patients in 2025. As the healthcare landscape transforms, these three companies offer stand-out opportunities amid uncertain markets. With these companies' blend of innovation and strong fundamentals, they provide a defensive anchor along with room for growth. These three stocks are well-positioned to deliver meaningful returns. It's a good idea to consider adding this trio into your buy watchlist of growth stocks. Generative AI is reshaping the stock market, but not in the way most investors think. It's not just about which companies are using AI. It's about how they're using it to unlock new revenue, dominate their markets, and quietly reshape the business world. Our latest FREE report 'How GenAI is Reshaping the Stock Market' breaks the hype down, so you can invest with greater clarity and confidence. Click here to download your copy today. Follow us on Facebook, Instagram and Telegram for the latest investing news and analyses! Disclosure: Gabriel Lim does not own shares in any of the companies mentioned. The post Maximise Your Portfolio's Returns with These 3 US Healthcare Stocks appeared first on The Smart Investor. Sign in to access your portfolio